These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 11353607)

  • 1. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.
    Fukuda H; Kishii R; Takei M; Hosaka M
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1649-53. PubMed ID: 11353607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
    Pan XS; Yague G; Fisher LM
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
    J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Coyle EA; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1654-9. PubMed ID: 11353608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae.
    Kishii R; Takei M; Fukuda H; Hayashi K; Hosaka M
    Antimicrob Agents Chemother; 2003 Jan; 47(1):77-81. PubMed ID: 12499172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciprofloxacin dimers target gyrase in Streptococcus pneumoniae.
    Gould KA; Pan XS; Kerns RJ; Fisher LM
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2108-15. PubMed ID: 15155208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
    Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
    Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary targets of fluoroquinolones in Streptococcus pneumoniae.
    Fukuda H; Hiramatsu K
    Antimicrob Agents Chemother; 1999 Feb; 43(2):410-2. PubMed ID: 9925547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
    Takei M; Fukuda H; Kishii R; Hosaka M
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3544-7. PubMed ID: 11709337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae.
    Roychoudhury S; Twinem TL; Makin KM; McIntosh EJ; Ledoussal B; Catrenich CE
    J Antimicrob Chemother; 2001 Jul; 48(1):29-36. PubMed ID: 11418510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.
    Alovero FL; Pan XS; Morris JE; Manzo RH; Fisher LM
    Antimicrob Agents Chemother; 2000 Feb; 44(2):320-5. PubMed ID: 10639357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
    Heaton VJ; Ambler JE; Fisher LM
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
    Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
    Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.
    Lu T; Zhao X; Drlica K
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2969-74. PubMed ID: 10582891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
    Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.